All questionsSafety: Leqvio (inclisiran), all indications6 questions · 1 sourceMonitoringWhen should LDL-C be checked after starting Leqvio?“Assess LDL-C when clinically indicated. The LDL-lowering effect of LEQVIO may be measured as early as 30 days after initiation and anytime thereafter without regard to timing of the dose.” (opens the source at this quote in a new tab)CopyFlagWarningsWhat are the contraindications for Leqvio?“LEQVIO is contraindicated in patients with a prior serious hypersensitivity reaction to inclisiran or any of the excipients in LEQVIO. Serious hypersensitivity reactions have included anaphylaxis and angioedema [see Adverse Reactions (6.2)].” (opens the source at this quote in a new tab)CopyFlagCan Leqvio cause allergic reactions?“Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported in patients treated with LEQVIO [see Adverse Reactions (6.2)]. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to seek medical attention promptly.” (opens the source at this quote in a new tab)CopyFlag“Hypersensitivity: anaphylaxis, angioedema, rash, pruritus, and urticaria.” (opens the source at this quote in a new tab)CopyFlagNote: The second passage lists hypersensitivity reactions identified during postmarketing use of Leqvio.SafetyDoes Leqvio cause anti-drug antibodies?“Samples from 1,830 adult patients in the placebo-controlled clinical trials were tested for ADA [see Clinical Studies (14)]. Confirmed positivity was detected in 33/1,830 (2%) patients prior to receiving LEQVIO and in 90/1,830 (5%) patients during the 18 months of treatment with LEQVIO.” (opens the source at this quote in a new tab)CopyFlag“There was no identified clinically significant effect of anti-inclisiran antibodies on pharmacodynamics, safety, or effectiveness of LEQVIO in adults and pediatrics during the placebo-controlled studies. However, the long- term consequences of continuing LEQVIO treatment in the presence of anti-inclisiran binding antibodies are unknown.” (opens the source at this quote in a new tab)CopyFlagDid Leqvio cause cancer in animal studies?“In a 2-year carcinogenicity study, Sprague-Dawley rats were administered subcutaneous doses of 40, 95, or 250 mg/kg inclisiran once every 28 days (1, 3, or 8 times the MRHD, based on BSA comparison/dose). Inclisiran was not carcinogenic up to the highest dose tested. In a 26-week study in RasH2Tg mice, subcutaneous doses of 300, 600, or 1,500 mg/kg once every 28 days were administered. Inclisiran was not carcinogenic up to the highest dose tested. Inclisiran was not mutagenic or clastogenic in a standard battery of genotoxicity tests, including a bacterial mutagenicity assay, an in vitro chromosome aberration assay using human peripheral lymphocytes, and an in vivo bone marrow micronucleus assay in rats.” (opens the source at this quote in a new tab)CopyFlagNote: These are nonclinical studies in rats and mice from the Prescribing Information.Does Leqvio prolong the QT interval?“At a dose 3 times the maximum recommended dose, inclisiran does not prolong the QT interval to any clinically relevant extent.” (opens the source at this quote in a new tab)CopyFlag